The Interatrial Shunts ecosystem comprises a defined set of upstream, midstream, and downstream actors that collectively enable the design, manufacture, distribution, and clinical adoption of shunt devices for heart failure management. Upstream activities involve raw‑material and component suppliers that provide biocompatible polymers, nitinol frames, and sealing membranes. Midstream participants—device manufacturers and system integrators—assemble these components into FDA‑cleared or CE‑marked shunt systems, embed delivery catheters, and generate the regulatory dossiers required for market entry. Device manufacturers often rely on contract manufacturing organizations to scale production, while system integrators coordinate with imaging equipment vendors to ensure compatibility with existing cath‑lab platforms. Intellectual property licensing between component innovators and OEMs further shapes the cost structure of the final shunt system. Downstream, distributors, hospital procurement groups, and interventional cardiology teams purchase and implant the devices, while post‑implant monitoring services capture outcomes that feed back into product improvement and reimbursement negotiations.
